血小板生成素与白介素-11治疗胃癌术后辅助化疗后血小板减少症时效及安全性的比较

目的:比较血小板生成素与白介素-11治疗胃癌患者术后化疗血小板减少症的时效和安全性。方法:术后辅助化疗出现血小板计数低于75×109/L的进展期胃癌患者68例,将其分为TPO组与IL-11组,分别为35例和33例。分别皮下注射rhTPO 15000U,每日1次;rhIL-11 1.5 mg,每日1次,当血小板计数125×109/L或比用药前上升50×109/L,即停止给药,疗程最长为14天。每3天抽取外周静脉血2 m L,通过全自动血液分析仪测定血小板计数,密切观察出现的不良反应并记录。比较两组患者不同临床病理资料、血小板计数、血小板计数升至75×109/L和125×109/L的时程、药物不良反应。结果:两组患者年龄、性别、化疗方案、血小板最低值出现的化疗周期及临床病理分期的比较均没有统计学差异(P值均0.05)。TPO组与IL-11组血小板动态值的比较,第9天出现显著差异(P=0.032)。TPO组与IL-11组血小板计数恢复至75×109/L和125×109/L所需的时间,有显著差异(P=0.041,P=0.013)。TPO组中,有3例(8.6%)患者发生不良反应,IL-11组中,有13例(39.4%)患者发生不良反应,TPO组患者出现的不良反应少且较轻微(P=0.006)。结论:rhTPO治疗胃癌患者术后化疗血小板减少症时效快,安全性好。     

Differential localization of P-selectin and von Willebrand factor during megakaryocyte maturation

Abstract

An important step in megakaryocyte maturation is the appropriate assembly of at least two distinct subsets of α-granules. The mechanism that sorts the α-granule components into distinct structures and mediates their release in response to specific stimuli is now emerging. P-selectin and von Willebrand factor are two proteins present in the α-granules that recognize P-selectin glycoprotein ligand on neutrophils and collagen in the subendothelial matrix. These proteins may play an important role in determining the differential release of the α-granule contents in response to external stimuli. If P-selectin and von Willebrand factor are localized in the same or different α-granules is not known. To clarify this question, we analyzed by immunoelectron microscopy the localization of von Willebrand factor and P-selectin during the maturation of wild-type and Gata1^low megakaryocytes induced in vivo by treating animals with thrombopoietin. Gata1^low is a hypomorphic mutation that blocks megakaryocyte maturation, reduces the levels of von Willebrand factor expression and displaces P-selectin on the demarcation membrane system. The maturation block induced by this mutation is partially rescued by treatment in vivo with thrombopoietin. In immature megakaryocytes, both wild-type and Gata1^low, the two receptors were co-localized in the same cytoplasmic structures. By contrast, the two proteins were segregated to separate α-granule subsets as the megakaryocytes matured. These observations support the hypothesis that P-selectin and von Willebrand factor may ensure differential release of the α-granule content in response to external stimuli.     

人血小板生成素氨基端功能区cDNA的克隆及其定点突变

以Nested－PCR方法从人肝cDNA基因文库中扩增出编码人血小板生成素（hTPO）前153个氨基酸的氨基端功能区cDNA;在扩增中,采用非连续多核甘酸定点突变的方法．将翻译起始的七个氨基酸的原核中不常用的密码子同又突变成使用频率较高的密码子,以便于其在大肠杆菌中表达。序列测定证实了预期的结果。     

血小板生成素研究进展

血小板生成素(thrombopoietin,TPO)是近几年发现的一种造血生长因子,其功能是促进巨核细胞的发育成熟,调节血液中血小板的水平。由于它在临床上纠正较难对付的血小板减少症方面具有较好的应用前景,短短两年时间其开发研究已进入了Ⅰ/Ⅱ期临床试验,据称初步结果比较乐观;在理论研究方面,TPO基因的克隆大大丰富了人们对巨核细胞发育过程和调控机制的认识,出现了大量相关文献。本文根据最新文献,综述人们在有关TPO的表达调控、信号转导、生物活性、临床应用等方面的认识。     

Construction of a fusion protein between N-terminal 153 peptide of thrombopoietin and erythropoietin

Ｔｈｒｏｍｂｏｐｏｉｅｔｉｎ(ＴＰＯ)ｉｓａｈｅｍａｔｏｐｏｉｅｔｉｃｃｙｔｏｋｉｎｅｃｌｏｎｅｄｉｎｒｅｃｅｎｔｙｅａｒｓ[1—3].Ｉｔｓｆｕｎｃｔｉｏｎｉｓｔｏｒｅｇｕｌａｔｅｔｈｅｆｏｒｍａｔｉｏｎｏｆｐｌａｔｅｌｅｔ,ｗｈｉｃｈｐｌａｙｓａｎｉｍｐｏｒｔａｎｔｒｏｌｅｉｎｂｌｏｏｄｃｌｏｔｔｉｎｇ,ｂｙｓｔｉｍｕｌａｔｉｎｇｔｈｅｓｔｅｍｃｅｌｌｓｔｏｄｉｆｆｅｒｅｎｔｉａｔｅａｎｄｄｅｖｅｌｏｐｉｎｔｏｍａｔｕｒｅｍｅｇａｋａｒｙｏｃｙｔｅｓ.Ｔｈｅｒｅｓｕｌｔｓｏｆａｎｉｍａｌｅｘｐｅｒｉｍ…     

重组人血小板生成素早期干预救治重症急性放射病猴的实验研究

重组人血小板生成素（rhTPO）是一种能促进巨核系祖细胞增殖、分化生成血小板的造血因子,研究表明它能促进射线照射小鼠造血功能恢复,前期工作证明rhTPO早期干预可显著提高致死剂量照射小鼠的活存率.本文以7.0Gy照射恒河猴为重度骨髓型急性放射病（ARS）模型,研究了rhTPO早期干预对重症ARS的治疗作用,并与WR2721和＂500＂的辐射防护作用进行了比较,结果发现rhTPO早期干预可明显促进ARS猴造血功能恢复,改善ARS猴症状,简化对症治疗措施,提高重度骨髓型ARS猴活存率,其对重度骨髓型ARS的防治作用优于现有的辐射防护药WR2721和＂500＂,有望开发成安全有效的新型辐射防治药物.     

Effect of doxycycline-regulated calnexin and calreticulin expression on specific thrombopoietin productivity of recombinant Chinese hamster ovary cells

In an attempt to increase the specific thrombopoietin (TPO) productivity (q(TPO)) of recombinant Chinese hamster ovary (rCHO) cells (CHO-TPO), the effect of expression level of calnexin (CNX) and calreticulin (CRT) on q(TPO) was investigated. To control both CNX and CRT expression levels simultaneously, the Tet-Off system was first introduced in CHO-TPO cells, and stable Tet-Off cells (TPO-Tet-Off) were screened by luciferase assay. The doxycycline-regulated CNX and CRT expression system in rCHO cells (TPO-CNX/CRT) was established by cotransfection of CNX and CRT expression vector and pTK-Hyg vector into TPO-Tet-Off cells and subsequent screening by Western blot analysis of CNX and CRT. The expression levels of CNX and CRT in TPO-CNX/CRT cells could be tightly controlled by adding different concentrations of doxycycline to a culture medium. Compared with the basal level (2 microg/mL doxycyline), a 2.9-fold increase in CNX expression and a 2.8-fold increase in CRT expression were obtained in the absence of doxycycline. This, in turn, resulted in a 1.9-fold increase in q(TPO), not inhibiting cell growth or changing in vivo biological activity of TPO. Taken together, these results demonstrate that a simultaneous overexpression of CNX and CRT can increase the q(TPO) of rCHO cells.     

His499 Regulates Dimerization and Prevents Oncogenic Activation by Asparagine Mutations of the Human Thrombopoietin Receptor

Ligand binding to the extracellular domain of the thrombopoietin receptor (TpoR) imparts a specific orientation on the transmembrane (TM) and intracellular domains of the receptors that is required for physiologic activation via receptor dimerization. To map the inactive and active dimeric orientations of the TM helices, we performed asparagine (Asn)-scanning mutagenesis of the TM domains of the murine and human TpoR. Substitution of Asn at only one position (S505N) activated the human receptor, whereas Asn substitutions at several positions activated the murine receptor. Second site mutational studies indicate that His⁴⁹⁹ near the N terminus of the TM domain is responsible for protecting the human receptor from activation by Asn mutations. Structural studies reveal that the sequence preceding His⁴⁹⁹ is helical in the murine receptor but non-helical in peptides corresponding to the TM domain of the inactive human receptor. The activating S505N mutation and the small molecule agonist eltrombopag both induce helix in this region of the TM domain and are associated with dimerization and activation of the human receptor. Thus, His⁴⁹⁹ regulates the activation of human TpoR and provides additional protection against activating mutations, such as oncogenic Asn mutations in the TM domain.     

血小板生成素改构体基因的克隆和序列分析

采用PCR技术,根据文献报道的鼠TPO成熟肽基因序列,设计并合成两对引物,以鼠TPO cDNA为模板,扩增获得mTPO N端153个氨基酸的478bp cDNA片段及鼠TPO全长1032bp cDNA片段,mTPO153片段与合成的碱性成纤维生长因子序列中Lys119-Lys135as的51bp肝素结合位点DNA片段连接,克隆到M13mp18及M13mp19载体中进行双向测序;同时将扩增的鼠TPO全长cDNA片段克隆到M13mp18及M13mp19载体中进行双向测序。证明获得鼠血小板生成素与肝素结合位点基因及鼠TPO全长基因,继之以pMAL-C2X为表达载体构建表达质粒,并经PCR及酶切鉴定。